MariMed is monitoring the spread of COVID-19 in the U.S. and proactively working across each of our business units to minimize its impact on the supply chain. Our first priority is to ensure medical cannabis patients continue to have access to the medicine they need at a time when they may be especially vulnerable. While...
MariMed Inc. Financials – The Rest Of The Story Sep. 20, 2019 9:56 AM ET https://seekingalpha.com/article/4292668-marimed-inc-financials-rest-story About: MariMed Inc. (MRMD), Includes: ALEAF, ITHUF, LHSIF, MMNFF, ORHOF, TGODF James Coleman Special situations, value, long/short equity (487 followers) Summary On 8/12/19 MariMed Inc. reported record Q2 sales and earnings. However, as of 9/17/19 the stock has declined by ~38% since then. YTD MRMD has plummeted 68%...
How one molecule from the cannabis plantcame to be seen as a therapeutic cure-all. By MOISES VELASQUEZ-MANOFF MAY 14, 2019 Originally Posted on New York Times When Catherine Jacobson first heard about the promise of cannabis, she was at wits’ end. Her 3-year-old son, Ben, had suffered from epileptic seizures since he was 3 months...
This article originally appeared in Motley Fool. This article was written by Keith Speights. You can count the number of multibillion-dollar marijuana markets, at least of the legal variety, on one hand and still have some fingers left over. Even then, several of those markets haven’t topped more than $2 billion in annual legal marijuana sales yet....
IN THE NEWSFive Marijuana Stocks With Huge Growth Potential : CGC, ACB, CRON, TLRY & MRMD
March 18, 2019by MariMed Team
This article originally appeared in InvestorObserver written by Michael Fowkles. Weed, marijuana, pot, cannabis, loud, Mary Jane, sticky icky, green, chronic, tea… Whatever you call it, it is a growing market in the United States. Ten or fifteen years ago you would have been laughed out of a room if you brought up the idea of legalized marijuana...
This article originally appeared in Motlet Fool. This article was written by Keith Speights. Auxly Cannabis (NASDAQOTH:CBWTF) and MariMed (NASDAQOTH:MRMD) aren’t your run-of-the-mill marijuana stocks. Both Auxly and MariMed claim characteristics that differentiate them from the rest of the pack. The Case for MariMed MariMed isn’t profitable yet, either. However, the company’s revenue has steadily increased to nearly $3.4 million in the...
This article originally appeared in Motley Fool. This article was written by Keith Speights. Cronos Group (NASDAQ:CRON) and MariMed (NASDAQOTH:MRMD) accomplished something in 2018 that most marijuana stocks didn’t: They delivered positive returns. Both stocks crushed the performances of the top marijuana exchange-traded funds (ETFs). MariMed was, by far, the bigger winner, with its stock skyrocketing 371% compared to Cronos Group’s 34% gain. But...
IN THE NEWS11 Company Pitches From Benzinga’s Cannabis Capital Conference
January 28, 2019by MariMed Team
This article originally appeared in Benzinga. This article was written by Rachelle Gordon. Benzinga’s Cannabis Capital Conference brought major companies in the space face-to-face with investors in Miami Beach last week. The following are key takeaways from their presentations. MariMed The company provides a variety of services for the cannabis industry across multiple verticals. MariMed Inc MRMD 3.25% is a multistate...
IN THE NEWSThese 3 Stocks Trounced the Top Marijuana ETFs in 2018, and Here’s Why They’ll Do It Again This Year
January 14, 2019by MariMed Team
Article originally appeared in The Motley Fool. by Keith Speights There’s also some great news, though, if you’re willing to invest in individual marijuana stocks rather than ETFs: Several marijuana stocks handily outperformed both the Horizons and ETFMG ETFs. I think there are three such stocks that trounced these ETFs and are likely to do it again in...
Article originally appeared in The Motley Fool. by George Budwell Cannabis, in many ways, became a legitimate investing arena in 2018. Even so, the nascent cannabis space still has a long way to go before many of its most serious risk factors are a thing of the past. Fortunately, there are a handful of companies operating in less controversial...